RxDoctor Payments Data

Angie Goodman, DPM

Podiatrist · Findlay, OHNPI 1790002004

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (56.7%), travel and lodging and education — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Paragon 28, Inc. at 36.9% of the total. Reporting peaked in 2023 at $1,975 and has fallen 86.4% since, to $269 in 2025.

$4,825in general payments, 2019–2025

Across 118 payments — averaging $40.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Paragon 28, Inc.$2K
  • CDC Medical LLC$872
  • Novo Nordisk$554
  • Stryker$472
  • Medtronic$162
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$86
  • plus $898 from 23 others

What the payments were for

  • Travel & lodging$1,21825%
  • Food & beverage$2,73557%
  • Education$87218%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,825 in reported general payments places this provider in the 80th percentile of 397 podiatrist providers in Ohio.

See all podiatrist providers in Ohio →

Medicare billing

Part B allowed, 2024
$55,889
Medicare patients
165
Services billed
777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciclopirox33$858
Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort18$757
Nystatin11$684
Pregabalin15$471
Ammonium Lactate17$404
Terbinafine Hcl18$379
Ketoconazole14$344
Gabapentin11$167
Doxycycline Hyclate12$118
Mupirocin14$91
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$69
Methylprednisolone12$61
Meloxicam25$33

Paid to pharmacies, not to this prescriber.

Other podiatrist in Findlay

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →